Literature DB >> 25695162

Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.

Jon J G Winter1, Malcolm Anderson, Kevin Blades, Claire Brassington, Alexander L Breeze, Christine Chresta, Kevin Embrey, Gary Fairley, Paul Faulder, M Raymond V Finlay, Jason G Kettle, Thorsten Nowak, Ross Overman, S Joe Patel, Paula Perkins, Loredana Spadola, Jonathan Tart, Julie A Tucker, Gail Wrigley.   

Abstract

Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and GTPase-activating protein-catalyzed mechanisms, resulting in the perpetual activation of Ras pathways. We describe a fragment screening campaign using X-ray crystallography that led to the discovery of three fragment binding sites on the Ras:SOS complex. The identification of tool compounds binding at each of these sites allowed exploration of two new approaches to Ras pathway inhibition by stabilizing or covalently modifying the Ras:SOS complex to prevent the reloading of Ras with GTP. Initially, we identified ligands that bound reversibly to the Ras:SOS complex in two distinct sites, but these compounds were not sufficiently potent inhibitors to validate our stabilization hypothesis. We conclude by demonstrating that covalent modification of Cys118 on Ras leads to a novel mechanism of inhibition of the SOS-mediated interaction between Ras and Raf and is effective at inhibiting the exchange of labeled GDP in both mutant (G12C and G12V) and wild type Ras.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25695162     DOI: 10.1021/jm501660t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

Review 1.  Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.

Authors:  Shaoyong Lu; Hyunbum Jang; Shuo Gu; Jian Zhang; Ruth Nussinov
Journal:  Chem Soc Rev       Date:  2016-07-11       Impact factor: 54.564

Review 2.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

3.  Allosteric KRas4B Can Modulate SOS1 Fast and Slow Ras Activation Cycles.

Authors:  Tsung-Jen Liao; Hyunbum Jang; David Fushman; Ruth Nussinov
Journal:  Biophys J       Date:  2018-07-24       Impact factor: 4.033

4.  Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V).

Authors:  Adam M Levinson; John H McGee; Andrew G Roberts; Gardner S Creech; Ting Wang; Michael T Peterson; Ronald C Hendrickson; Gregory L Verdine; Samuel J Danishefsky
Journal:  J Am Chem Soc       Date:  2017-05-22       Impact factor: 15.419

Review 5.  Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.

Authors:  Jonathan M L Ostrem; Kevan M Shokat
Journal:  Nat Rev Drug Discov       Date:  2016-07-29       Impact factor: 84.694

Review 6.  Twenty years on: the impact of fragments on drug discovery.

Authors:  Daniel A Erlanson; Stephen W Fesik; Roderick E Hubbard; Wolfgang Jahnke; Harren Jhoti
Journal:  Nat Rev Drug Discov       Date:  2016-07-15       Impact factor: 84.694

7.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Authors:  Paul Morgan; Dean G Brown; Simon Lennard; Mark J Anderton; J Carl Barrett; Ulf Eriksson; Mark Fidock; Bengt Hamrén; Anthony Johnson; Ruth E March; James Matcham; Jerome Mettetal; David J Nicholls; Stefan Platz; Steve Rees; Michael A Snowden; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2018-01-19       Impact factor: 84.694

8.  Structural basis of the atypical activation mechanism of KRASV14I.

Authors:  Asim K Bera; Jia Lu; Thomas E Wales; Sudershan Gondi; Deepak Gurbani; Andrew Nelson; John R Engen; Kenneth D Westover
Journal:  J Biol Chem       Date:  2019-07-24       Impact factor: 5.157

Review 9.  RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.

Authors:  Bingliang Fang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-09-07       Impact factor: 3.848

10.  A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.

Authors:  Arsheed A Ganaie; Hifzur R Siddique; Ishfaq A Sheikh; Aijaz Parray; Lei Wang; Jayanth Panyam; Peter W Villalta; Yibin Deng; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Carcinog       Date:  2020-04-15       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.